By Frank Prenesti
Date: Wednesday 26 Apr 2023
LONDON (ShareCast) - (Sharecast News) - GSK first quarter profits and revenue both beat expectations driven by its shingles and meningitis treatments, among others.
The company posted revenue of £7bn against expectations of £6.5bnm according to company-compiled estimates. Adjusted operating profit rose 8% to £2.1bn as GSK also maintained full-year guidance.
Its shingles vaccine, Shingrix, generated sales of £833m, beating estimates of £829m.
Reporting by Frank Prenesti for Sharecast.com
Email this article to a friend
or share it with one of these popular networks:
Currency | UK Pounds |
Share Price | 1,775.00p |
Change Today | -8.50p |
% Change | -0.48 % |
52 Week High | 1,812.50p |
52 Week Low | 1,316.00p |
Volume | 9,685,447 |
Shares Issued | 4,144.92m |
Market Cap | £73,572m |
RiskGrade | 129 |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
Strong Buy | 8 |
Buy | 5 |
Neutral | 9 |
Sell | 2 |
Strong Sell | 0 |
Total | 24 |
Latest | Previous | |
---|---|---|
Q1 | Q4 | |
Ex-Div | 16-May-24 | 22-Feb-24 |
Paid | 11-Jul-24 | 11-Apr-24 |
Amount | 15.00p | 16.00p |
Time | Volume / Share Price |
16:51 | 423 @ 1,775.00p |
16:37 | 20,200 @ 1,771.97p |
16:36 | 10,580 @ 1,775.00p |
16:35 | 3,357,820 @ 1,775.00p |
16:35 | 2,092 @ 1,775.00p |
You are here: research